FibroBiologics (Direct Listing) FBLG 深 滬
已收盤 09-19 16:00:00 美东时间
3.16
-0.080
-2.47%
華盛通- 最 高3.595
- 今 開3.43
- 成交量 41.28万股
- 最 低 3.15
- 昨 收 3.24
- 總市值 1.03亿
- 52周最高 55.00
- 市盈率 靜 --
- 換手率 1.26%
- 52周最低 1.0779
- 委 比 42.70%
- 總股本 3263.44万
- 歷史最高 55.00
- 量 比 0.75
- 振 幅 13.73%
- 歷史最低 1.0779
- 每 手 1
- 風險率 4.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EF Hutton Maintains Buy on FibroBiologics, Maintains $16 Price Target
EF Hutton analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.
09-13 19:56
美股牛股 | 生物制药公司SMMT再涨20%，近两个交易日累涨87%；康丽数码飙升20%
新药疗效击败默沙东！生物制药公司SMMT再涨20%，近两个交易日累涨87%；宣布启动1亿美元股票回购计划，康丽数码飙升20%>>
09-11 19:14
FibroBiologics Raises Funds Through Strategic Equity Sales to GEM
The latest announcement is out from FibroBiologics, Inc. (FBLG). FibroBiologics...
08-28 04:30
FibroBiologics Q2 EPS $0.03 Beats $(0.09) Estimate; Cash $5.973M
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.09) by 133.33 percent. This is a 137.5 percent increase over losses of
08-08 14:40
美股牛股 | Smartsheet升17%，多家投行上调目标价；万达生物制药隔夜涨24.2%
Smartsheet隔夜升17%，公司Q1业绩表现亮眼，富国等多家投行上调目标价；万达生物制药隔夜涨24.2%，传Cycle Pharmacecals提出每股8美元收购要约>>
06-07 16:56
FibroBiologics GAAP EPS of -$0.27
FibroBiologics press release (NASDAQ:FBLG): Q1 GAAP EPS of -$0.27. Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of ...
05-16 03:24
FibroBiologics files to sell 1.8M units
FibroBiologics (NASDAQ:FBLG) filed a prospectus related to the sale of 1.8M units at an assumed public offering price of $11.1 per unit. Each unit consists of one share, and one warrant to buy one sh...
04-27 03:23
FibroBiologics shares are trading higher after the company announced preliminary proof-of-concept for fibroblast-based diabetes treatment.
FibroBiologics shares are trading higher after the company announced preliminar...
03-20 02:51
FibroBiologics Announces Preliminary Proof Of Concept For Fibroblast-Based Diabetes Treatment
FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic
03-19 21:33
FibroBiologics to Present at Advanced Wound Care Summit USA
HOUSTON, March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on t...
03-13 21:31
